• Supplied

Minecorp Australia is supporting Rheinmetall Defence Australia with local component manufacture for the Lynx KF41 Infantry Fighting Vehicle.

Minecorp’s in-house engineering team is working to assist the Lynx KF41 assembly with a range of critical bracketry and vehicle components as Rheinmetall prepares for the Risk Mitigation Activity (RMA) trials for the $18.1-27.1 billion Land 400 Phase 3 program.

A privately-owned company, Minecorp manufactures and distributes products globally and is located in Brisbane.

General Manager Angus McIntyre said joining Team Lynx for Land 400 Phase 3 was an important step for the company.

“Our manufacturing capability and customer solutions focus are well honed to provide the support required for the Rheinmetall program,” McIntyre said. “To be part of an extensive local supplier base here in Queensland proves that production in Australia is still strong, and we intend to continue building our expertise in this area. We are extremely proud of our design and manufacturing capability - supporting sovereign capability is a key deliverable for our business.”

Rheinmetall will deliver three Lynx vehicles to compete in RMA trials, which will put vehicles through lethality, mobility and blast tests.

If successful, the Lynx fleet will be manufactured in Queensland at Rheinmetall’s new Military Vehicle Centre of Excellence at Redbank south west of Brisbane.

Minecorp says it has 'worked hard' over the past five years to learn and understand the nature of the Defence sector and adapt to the specific requirements. Utilising Trumpf CNC equipment and certified welding practices, the business 'understands time critical production ensuring all components meet the specified end use requirements.'

“We very much look forward to strengthening our partnership with RDA and extending our support with the LYNX KF41 program into the future," McIntyre said.

Yesterday, Hanwha launched its competitor for Land 400 Phase 3, the Redback Infantry Fighting vehicle, ahead of the RMA trials.

comments powered by Disqus